House Panel Probes Wyeth Off-Label Allegations

Law360, New York (June 14, 2010, 11:44 AM EDT) -- The House Committee on Oversight and Government Reform has opened an investigation into claims that Wyeth Pharmaceuticals Inc. targeted blacks in an illegal off-label marketing scheme for kidney transplant drug Rapamune.

Oversight Committee chairman Edolphus Towns, D-N.Y., sent a letter Friday to Pfizer Inc. CEO and chairman Jeffrey Kindler notifying him that the committee will be investigating whether Wyeth — acquired by Pfizer in October — “aggressively encouraged the use of Rapamune to prevent organ rejection following heart, lung, liver, pancreas and islet cell transplants, without...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.